Ampreloxetine (TFA)

Ampreloxetine (TD-9855) TFA is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine TFA has the potential for the research of neurogenic orthostatic hypotension[1][2].

Product Specifications

CAS Number

[1227056-85-0]

Product Name Alternative

TD-9855 (TFA)

UNSPSC

12352005

Target

5-HT Receptor; Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ampreloxetine-tfa.html

Purity

98.30

Solubility

DMSO : ≥ 100 mg/mL

Smiles

FC1=C(OCC2=CC=CC=C2C3CCNCC3)C(F)=CC(F)=C1.O=C(O)C(F)(F)F

Molecular Formula

C20H19F6NO3

Molecular Weight

435.36

References & Citations

[1]Smith JA, et al. Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18 (2) :pyu027. |[2]Kaufmann H, et al. Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin Auton Res. 2021 Dec;31 (6) :699-711.